| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Divisions of Clinical Chemistry (K.W., M.M.H., I.F., H.W., W.M.) and Sports Medicine (M.W.B.), Department of Medicine, Albert Ludwigs-University, D-79106 Freiburg, Germany; and Medical Department (C.A.), Novartis Pharma GmbH, D-90429 Nürnberg, Germany
Address all correspondence and requests for reprints to: Karl Winkler, M.D., Department of Medicine, Hugstetter Strasse 55, D-79106 Freiburg, Germany. E-mail: kwinkler{at}ukl.uni-freiburg.de.
Abstract
The objective of this study was to determine the effect of slow-release (XL) fluvastatin on low density lipoprotein (LDL) subfractions in type 2 diabetes. A multicenter, double-blind, randomized, parallel-group comparison of fluvastatin XL 80 mg (n = 42) and placebo (n = 47), each given once-daily for 8 wk, in 89 patients with type 2 diabetes (HbA1c: 7.2 ± 1.0%, LDL cholesterol (LDL-C): 3.4 ± 0.7 mmol/liter, high density lipoprotein cholesterol: 1.1 ± 0.3 mmol/liter, and triglycerides (TG): 2.4 ± 1.4 mmol/liter). At baseline and on treatment, plasma lipoproteins were isolated and quantified. Eight weeks of fluvastatin treatment decreased total cholesterol (–23.0%, P < 0.001), LDL-C (–29%, P < 0.001) and TG (–18%, P < 0.001), compared with placebo. At baseline, there was a preponderance of dense LDL (dLDL) (apolipoprotein B in LDL-5 plus LDL-6 > 25 mg/dl) in 79% of patients, among whom fluvastatin decreased all LDL subfractions, reductions in dLDL being greatest (–28%, P = 0.001; cholesterol in dLDL –29%). In patients with low baseline dLDL (apolipoprotein B in LDL-5 plus LDL-6 
25 mg/dl), but a preponderance of buoyant LDL (LDL-1 through LDL-3), fluvastatin significantly decreased only these subfractions. Fluvastatin 80 mg XL, once daily, decreased total cholesterol and total LDL-C. In patients with atherogenic dLDL, absolute changes of dLDL were most pronounced, emphasizing the value of fluvastatin treatment in type 2 diabetes. The antiatherogenic potential of fluvastatin in type 2 diabetes may thus be greater than that expected from its effects on LDL-C and TG alone.
This article has been cited by other articles:
 |
|
 |
|
  J. Costa, M. Borges, C. David, and A. Vaz Carneiro Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials BMJ, May 13, 2006; 332(7550): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Backes and C. A Gibson Effect of Lipid-Lowering Drug Therapy on Small-Dense Low-Density Lipoprotein Ann. Pharmacother., March 1, 2005; 39(3): 523 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Winkler, C. Abletshauser, I. Friedrich, M. M. Hoffmann, H. Wieland, and W. Marz Fluvastatin Slow-Release Lowers Platelet-Activating Factor Acetyl Hydrolase Activity: A Placebo-Controlled Trial in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1153 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Sacks and H. Campos Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study Diabetes Care, September 1, 2003; 26(9): 2588 - 2594. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
